The development of neutralizing anti-factor VIII (fVIII) antibodies, inhibitors, is the most significant complication affecting treated patients with hemophilia A (HA). Once an inhibitor develops, treatment is less effective and costly. Although inhibitors occur most commonly in those with severe HA, 25% of new inhibitors occur in patients with mild and moderate HA. To date, studies that seek to understand risk factors for inhibitor development in those with mild and moderate HA have been limited to retrospective analyses and have identified intensive fVIII treatment and surgery as risk factors. Receiving fVIII by continuous infusion has been associated with inhibitor development in mild and moderate HA in some but not all studies. Accordingly, the next logical step to evaluate the risk of inhibitor development is a prospective observational cohort study. If continuous fVIII infusion is associated with inhibitor development, it may be due in part to the promotion a more robust pro-inflammatory response. Toward my long-term goal of reducing the incidence of new inhibitors in HA, the objective of this application is to identify how and why the immune response to fVIII in patients with mild and moderate HA varies between those that develop and inhibitor and those that do not.
Specific Aim 1 will test the hypothesis that the method of peri-operative fVIII delivery in subjects with mild and moderate HA is associated with inhibitor development. To test this we will perform a multicenter prospective observational cohort study enrolling 140 subjects with mild and moderate HA undergoing a surgical procedure. The association between fVIII delivery by continuous infusion and inhibitor development will adjusted for confounding variables such as type of surgery, operative time, fVIII level, and extent of prior fVIII exposure. We anticipate that there will be a greater proportion of inhibitors formed in subjects who receive fVIII delivered by continuous infusion. We also anticipate that the dose fVIII delivered and the type of surgery performed will be mediating factors that attenuate this relationship.
Specific Aim 2 will test the hypothesis that inhibitor development in patients with mild and moderate HA undergoing surgery is associated with: 1) post-operative increases in inflammatory cytokines and 2) deviation toward a T helper (TH) 2 adaptive immune response. We anticipate that subjects with increased in proinflammatory cytokines on post-operative day 7 will have a predominantly TH2 response to fVIII and a higher proportion of inhibitor development compared with subjects with little or no increase in proinflammatory cytokines. The results of these experiments will provide significant insight into the immune response to fVIII in the setting of surgery and provide important basic immunologic background to facilitate the design of treatment strategies to reduce inhibitor development in patients with HA. In addition to completion of the Specific Aims, the proposed career development activities will take place at Emory University, a robust and productive research environment, and include: 1) directed course work, 2) conference participation;3) hands-on laboratory skill development, and 3) close mentorship by Drs. Lollar, Zimring and Mertens. These activities will build on my current foundation in laboratory and clinical research and greatly enhance my development toward an independent clinical investigator.

Public Health Relevance

Patients with hemophilia A (HA) have a deficiency factor VIII (fVIII). Some patients develop antibody to replacement fVIII which makes treatment more difficult to treat and costly. In this project, we will develop a better understanding of why some people develop inhibitors to fVIII.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-X (O1))
Program Officer
Sarkar, Rita
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
Schools of Medicine
United States
Zip Code
Eubanks, Joshua; Baldwin, W Hunter; Markovitz, Rebecca et al. (2016) A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII. Blood 127:2028-34
Kempton, C L; Antun, A; Antoniucci, D M et al. (2014) Bone density in haemophilia: a single institutional cross-sectional study. Haemophilia 20:121-8
McNamara, M; Antun, A; Kempton, C L (2014) The role of disease severity in influencing body mass index in people with haemophilia: a single-institutional cross-sectional study. Haemophilia 20:190-5
Baumgardner, J; Elon, L; Antun, A et al. (2013) Physical activity and functional abilities in adult males with haemophilia: a cross-sectional survey from a single US haemophilia treatment centre. Haemophilia 19:551-7
Lane, Jérôme; McLaren, Paul J; Dorrell, Lucy et al. (2013) A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Hum Mol Genet 22:1903-10
Kempton, Christine L; Allen, Geoff; Hord, Jeffrey et al. (2012) Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol 87:933-6
Kempton, C L (2010) Inhibitors in previously treated patients: a review of the literature. Haemophilia 16:61-5